Contineum Therapeutics, Inc. (CTNM) research
Contineum Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $13.40
- As of
Contineum Therapeutics, Inc. (CTNM): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
As of . Source: SEC EDGAR filings for CTNM. Method and limitations.
Share the CTNM intelligence card
See CTNM live in the terminal
Track CTNM's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live CTNM terminal, freeActive signals for CTNM
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 70% of CTNM (2026Q2)
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in CTNM
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 70% of CTNM (2026Q2)
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in CTNM
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 70% of CTNM (2026Q2)
FREE, NO ACCOUNT
Every signal on CTNM, as it fires
You are seeing 5 of 14 signals recorded on CTNM since 2026-05-16.
The five above landed across 2 days. The other 9 were recorded on 3 other days. 9 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CTNM (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 21217B100 · 2026Q2 | $15.3M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 21217B100 · 2026Q2 | $6.5M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 21217B100 · 2026Q2 | $1.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 21217B100 · 2026Q2 | $497K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 21217B100 · 2026Q2 | $423K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CTNM
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
CTNM against its peers
CTNM's return on equity of -23.0% ranks in the 79th percentile of 20 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | CTNM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 9.7M | n/a | 13 |
| Operating margin | n/a | -285.9% | n/a | 10 |
| Net margin | n/a | -221.7% | n/a | 10 |
| Return on equity | -23.0% | -65.8% | 79 | 20 |
Peers (20): ASMB, KYTX, MPLT, AUTL, PBYI, ENTX, OVID, CAPR, TECX, RGNX, ARVN, OCS, PRME, EPRX, INDP, SPRY, PRTA, RLMD, ALLO, CABA. Left out: VOGX (no annual filing), EIKN (no annual filing), DRUG (period gap), AGMB (no annual filing), SCTX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (CTNM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CTNM signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CTNMand get the insider, 13F, options, and confluence read in one view.